PE20000013A1 - Derivados de adenosina - Google Patents

Derivados de adenosina

Info

Publication number
PE20000013A1
PE20000013A1 PE1998001065A PE00106598A PE20000013A1 PE 20000013 A1 PE20000013 A1 PE 20000013A1 PE 1998001065 A PE1998001065 A PE 1998001065A PE 00106598 A PE00106598 A PE 00106598A PE 20000013 A1 PE20000013 A1 PE 20000013A1
Authority
PE
Peru
Prior art keywords
adenosine
disease
receptor
alkyl
deoxy
Prior art date
Application number
PE1998001065A
Other languages
English (en)
Spanish (es)
Inventor
Colin David Eldred
Richard Peter Charles Cousins
Andrew Michael Kenneth Pennell
Brian Cox
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20000013A1 publication Critical patent/PE20000013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE1998001065A 1997-11-08 1998-11-05 Derivados de adenosina PE20000013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9723589.9A GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds

Publications (1)

Publication Number Publication Date
PE20000013A1 true PE20000013A1 (es) 2000-01-21

Family

ID=10821760

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001065A PE20000013A1 (es) 1997-11-08 1998-11-05 Derivados de adenosina

Country Status (29)

Country Link
US (1) US6455510B1 (https=)
EP (2) EP1030857B1 (https=)
JP (1) JP2001522857A (https=)
KR (1) KR20010031875A (https=)
CN (1) CN1285843A (https=)
AP (1) AP2000001801A0 (https=)
AR (1) AR011229A1 (https=)
AT (1) ATE273990T1 (https=)
AU (1) AU2048399A (https=)
BR (1) BR9813976A (https=)
CA (1) CA2309200A1 (https=)
CO (1) CO5021135A1 (https=)
DE (1) DE69825780T2 (https=)
EA (1) EA200000392A1 (https=)
EE (1) EE200000285A (https=)
ES (1) ES2222621T3 (https=)
GB (1) GB9723589D0 (https=)
HR (1) HRP20000275A2 (https=)
HU (1) HUP0004082A2 (https=)
IL (1) IL135964A0 (https=)
IS (1) IS5477A (https=)
MA (1) MA26565A1 (https=)
NO (1) NO20002361L (https=)
PE (1) PE20000013A1 (https=)
PL (1) PL340921A1 (https=)
SK (1) SK6722000A3 (https=)
TR (1) TR200002131T2 (https=)
WO (1) WO1999024449A2 (https=)
ZA (1) ZA9810125B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
EP1434782A2 (en) 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US7265111B2 (en) 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
JP4596913B2 (ja) * 2002-08-15 2010-12-15 ギリアード・パロ・アルト・インコーポレイテッド Ａ１アデノシン受容体の部分および完全アゴニスト
KR20050097971A (ko) 2003-02-03 2005-10-10 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ₁아데노신 수용체의 부분 및 전 작용제
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP2008512457A (ja) * 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP2011509305A (ja) * 2008-01-09 2011-03-24 ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー Ａ２ａｒアゴニストによる神経障害性疼痛の髄腔内治療
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
JP2026500305A (ja) 2022-12-16 2026-01-06 アストラゼネカ・アクチエボラーグ ２，６，９三置換プリン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575959A (en) * 1969-05-13 1971-04-20 Merck & Co Inc 5'-substituted ribofuranosyl nucleosides
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
TR200002131T2 (tr) 2001-01-22
HRP20000275A2 (en) 2000-12-31
EP1030857A2 (en) 2000-08-30
NO20002361D0 (no) 2000-05-05
SK6722000A3 (en) 2001-01-18
ES2222621T3 (es) 2005-02-01
HUP0004082A2 (hu) 2001-04-28
DE69825780T2 (de) 2005-01-13
IS5477A (is) 2000-05-03
EE200000285A (et) 2001-08-15
US6455510B1 (en) 2002-09-24
AP2000001801A0 (en) 2000-06-30
ZA9810125B (en) 2000-05-05
CO5021135A1 (es) 2001-03-27
EP1457495A1 (en) 2004-09-15
NO20002361L (no) 2000-07-05
WO1999024449A3 (en) 1999-08-19
IL135964A0 (en) 2001-05-20
CN1285843A (zh) 2001-02-28
AU2048399A (en) 1999-05-31
ATE273990T1 (de) 2004-09-15
EP1030857B1 (en) 2004-08-18
PL340921A1 (en) 2001-03-12
BR9813976A (pt) 2000-09-26
AR011229A1 (es) 2000-08-02
DE69825780D1 (de) 2004-09-23
WO1999024449A2 (en) 1999-05-20
CA2309200A1 (en) 1999-05-20
JP2001522857A (ja) 2001-11-20
KR20010031875A (ko) 2001-04-16
GB9723589D0 (en) 1998-01-07
MA26565A1 (fr) 2004-12-20
EA200000392A1 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
PE20000013A1 (es) Derivados de adenosina
PE20000704A1 (es) Derivados de adenosina
PE20010039A1 (es) Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato
KR940007021A (ko) 흥분성 아미노산 수용체 길항물질
PE46899A1 (es) Derivados de n-fenil-sulfonamida
ES2175615T3 (es) Derivados de azaindol etilamina como agentes de union al receptor nicotinico de acetilcolina.
LU91073I2 (fr) EMTRICITABINE et ses dérivés pharmaceutiquement acceptables (EMTRIVA)
KR880011125A (ko) 헤테로 싸이클릭 화합물, 그의 제조방법 및 용도
KR840000568A (ko) 두고리 피리미딘-5-온 유도체의 제조방법
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
AR015238A1 (es) PROCESO PARA LA PREPARACIoN DE ETERES AMINICOS ESTERICAMENTE IMPEDIDOS, COMPOSICIONES, COMPUESTOS Y USO DE DICHOS COMPUESTOS COMO ESTABILIZANTES O RETARDANTES DE LLAMA, Y PROCESO PARA ESTABILIZAR UN MATERIAL ORGÁNICO
KR870007160A (ko) 신규의 디하이드로벤조푸란-및 크로만-카복스아미드 유도체, 그것의 제조 방법 및 신경이완제로서의 사용법
PE20000325A1 (es) Derivados de 2-ariletil-(piperidin-4-ilmetil)amina
EP0957080A4 (en) NEW ETHYLAMINE DERIVATIVES
KR900016196A (ko) 테트라하이드로벤즈[c, d]인돌 세로토닌 효능제
SE8505715D0 (sv) Indolderivat
RU94019425A (ru) Производные изатиноксима, способ их получения, фармацевтическая композиция и способ лечения
PE130999A1 (es) 4-oxo-naftiridin-3-carboxamidas sustituidas; ligandos de receptor cerebral gaba
ES2032570T3 (es) Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe).
DK132188A (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
KR900014388A (ko) 에세롤린의 카보네이트 유도체, 이의 제조방법 및 약제로서의 용도
RU2005100761A (ru) Амидзамещенные производные ксантина, обладающие модуляторной активностью в отношении биосинтеза глюкозы из неуглеводных субстратов
NO164593C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbamat- eller urea-derivater.
KR850007600A (ko) 테트라히드로티에노피리딘의 제조방법
MX9305300A (es) Nuevos derivados de 3-oxadiazolil-1-6-naftiridina y proceso para supreparacion.

Legal Events

Date Code Title Description
FC Refusal